Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMS30KU)

Drug Name

(R)-Norfluoxetine Drug Info

Synonyms

130194-43-3; UNII-05UQ1299DN; (R)-3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propylamine; CHEMBL446084; 05UQ1299DN; (R)-3-(4-Trifluoromethylphenoxy)-3-phenylpropylamine; Norfluoxetine, (R)-; (3r)-3-Phenyl-3-[4-(Trifluoromethyl)phenoxy]propan-1-Amine; R-Norfluoxetine; SCHEMBL3750512; CTK8E9557; MolPort-028-616-048; ZINC1645453; Benzenepropanamine, gamma-(4-(trifluoromethyl)phenoxy)-, (gammaR)-; BDBM50254791; 9049AH; AKOS027384575; NE64378; AJ-28674; RT-014016; FT-0673087; J-005760

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 9797657
CAS Number: CAS 130194-43-3
TTD Drug ID: DMS30KU

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine transporter (DAT)	TTVBI8W	SC6A3_HUMAN	Inhibitor	[1]
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[1]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Dopamine transporter (DAT)	DTT	SLC6A3	4	2.609	5.233	3.7
Norepinephrine transporter (NET)	DTT	SLC6A2	2.459	3.426	3.322	3.35
Serotonin transporter (SERT)	DTT	SLC6A4	6.278	5.469	6.075	6.966

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Dopamine transporter (DAT)	DTT	SLC6A3	1.08E-03	-3.08	-1.99
Serotonin transporter (SERT)	DTT	SLC6A4	8.76E-01	7.18E-05	6.19E-04

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.